Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
11 11월 2022 - 1:09AM
Edgar (US Regulatory)
0001671502--12-312022Q32022-09-30000-00000false00016715022022-01-012022-09-300001671502qnrx:BridgeWarrantsCommonStockMember2021-09-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-09-300001671502us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-09-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001671502us-gaap:FairValueMeasurementsRecurringMember2022-09-300001671502us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberqnrx:Notes2020WarrantsMember2021-12-310001671502us-gaap:FairValueMeasurementsRecurringMemberqnrx:Notes2020WarrantsMember2021-12-310001671502us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001671502us-gaap:FairValueMeasurementsRecurringMember2021-12-3100016715022022-09-302022-09-3000016715022021-12-312021-12-310001671502qnrx:QuoinPharmaceuticalsIncMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-092022-08-090001671502qnrx:PublicOfferingMember2022-08-092022-08-090001671502qnrx:BridgeNotesMemberdei:AdrMember2022-07-012022-09-300001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-03-012021-03-310001671502us-gaap:TreasuryStockCommonMember2022-09-300001671502us-gaap:RetainedEarningsMember2022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-09-300001671502us-gaap:TreasuryStockCommonMember2022-06-300001671502us-gaap:RetainedEarningsMember2022-06-300001671502us-gaap:AdditionalPaidInCapitalMember2022-06-3000016715022022-06-300001671502us-gaap:TreasuryStockCommonMember2022-03-310001671502us-gaap:RetainedEarningsMember2022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-03-3100016715022022-03-310001671502us-gaap:TreasuryStockCommonMember2021-12-310001671502us-gaap:RetainedEarningsMember2021-12-310001671502us-gaap:AdditionalPaidInCapitalMember2021-12-310001671502us-gaap:RetainedEarningsMember2021-09-300001671502us-gaap:AdditionalPaidInCapitalMember2021-09-300001671502us-gaap:RetainedEarningsMember2021-06-300001671502us-gaap:AdditionalPaidInCapitalMember2021-06-3000016715022021-06-300001671502us-gaap:RetainedEarningsMember2021-03-310001671502us-gaap:AdditionalPaidInCapitalMember2021-03-3100016715022021-03-310001671502us-gaap:RetainedEarningsMember2020-12-310001671502us-gaap:AdditionalPaidInCapitalMember2020-12-310001671502dei:AdrMemberqnrx:PublicOfferingMember2022-08-0900016715022021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-03-012022-03-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-07-012022-09-300001671502dei:AdrMember2021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-01-012022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-01-012022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-120001671502srt:MinimumMemberqnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-122022-04-120001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-04-122022-04-120001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2021-07-012021-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-07-012021-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2021-01-012021-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-01-012021-09-300001671502qnrx:ConsultingExpenseMember2022-07-012022-09-300001671502qnrx:ConsultingExpenseMember2022-01-012022-09-300001671502qnrx:ConsultingExpenseMember2021-07-012021-09-300001671502qnrx:ConsultingExpenseMember2021-01-012021-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-07-012022-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-01-012022-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-07-012021-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-01-012021-09-300001671502qnrx:BridgeNotesThirdPurchaseMay2021Member2021-03-242021-03-240001671502qnrx:BridgeNotesSecondPurchaseApril2021Member2021-03-242021-03-240001671502qnrx:BridgeNotesFirstClosingMarch252021Member2021-03-242021-03-240001671502us-gaap:RetainedEarningsMember2022-04-012022-06-300001671502us-gaap:RetainedEarningsMember2022-01-012022-03-310001671502us-gaap:RetainedEarningsMember2021-07-012021-09-300001671502us-gaap:RetainedEarningsMember2021-04-012021-06-3000016715022021-04-012021-06-300001671502us-gaap:RetainedEarningsMember2021-01-012021-03-3100016715022021-01-012021-03-3100016715022020-02-012020-02-290001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-06-302022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-03-012022-03-310001671502us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001671502us-gaap:LicensingAgreementsMember2022-09-300001671502us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001671502us-gaap:LicensingAgreementsMember2021-12-310001671502qnrx:Notes2020WarrantsMember2021-12-310001671502qnrx:Notes2020WarrantsMember2021-01-012021-12-3100016715022022-07-142022-07-140001671502dei:AdrMember2022-01-012022-09-300001671502dei:AdrMember2021-07-012021-09-300001671502dei:AdrMember2021-01-012021-09-300001671502qnrx:SalariesAndOtherCompensationMember2022-09-300001671502qnrx:InvoicesPaidOnBehalfOfCompanyMember2022-09-300001671502qnrx:SalariesAndOtherCompensationMember2021-12-310001671502qnrx:InvoicesPaidOnBehalfOfCompanyMember2021-12-310001671502qnrx:Convertiblenotes2020Member2022-08-090001671502qnrx:BridgeNotesMember2022-08-090001671502us-gaap:CommonStockMember2022-09-300001671502us-gaap:CommonStockMember2022-06-300001671502dei:AdrMember2022-06-300001671502us-gaap:CommonStockMember2022-03-310001671502dei:AdrMember2022-03-310001671502us-gaap:CommonStockMember2021-12-310001671502us-gaap:CommonStockMember2021-09-300001671502dei:AdrMember2021-09-300001671502us-gaap:CommonStockMember2021-06-300001671502dei:AdrMember2021-06-300001671502us-gaap:CommonStockMember2021-03-310001671502dei:AdrMember2021-03-310001671502us-gaap:CommonStockMember2020-12-310001671502dei:AdrMember2020-12-310001671502dei:AdrMember2021-12-310001671502qnrx:QuoinPharmaceuticalsIncMemberus-gaap:SubsequentEventMember2022-11-020001671502us-gaap:SubsequentEventMember2022-11-020001671502qnrx:QuoinPharmaceuticalsIncMember2022-04-110001671502qnrx:QuoinPharmaceuticalsIncMemberus-gaap:SubsequentEventMember2022-11-030001671502us-gaap:SubsequentEventMember2022-11-030001671502qnrx:QuoinPharmaceuticalsIncMember2022-04-120001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-09-300001671502qnrx:AltiumMemberdei:AdrMember2022-08-0200016715022022-07-140001671502qnrx:Convertiblenotes2020Member2022-09-300001671502qnrx:BridgeWarrantsCommonStockSecondAndThirdClosingsMember2022-09-300001671502qnrx:BridgeWarrantsCommonStockFirstClosingMember2022-09-300001671502qnrx:SeriesBWarrantsAmericanDepositarySharesMember2022-03-130001671502qnrx:SeriesaWarrantsAmericanDepositarySharesMember2022-03-130001671502qnrx:ConvertibleNotesWarrantsCommonStockMember2021-12-310001671502qnrx:BridgeWarrantsCommonStockMember2021-12-310001671502qnrx:ConvertibleNotesWarrantsCommonStockMember2020-12-310001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-090001671502qnrx:PreFundedWarrantsMemberqnrx:PublicOfferingMember2022-08-090001671502dei:AdrMember2022-04-020001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2022-09-300001671502qnrx:ExchangeWarrantsAmericanDepositarySharesMember2022-09-300001671502dei:AdrMember2022-09-300001671502qnrx:CommonWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-090001671502dei:AdrMember2022-08-020001671502qnrx:AltiumMemberdei:AdrMemberqnrx:AltiumAgreementMember2022-07-140001671502qnrx:AltiumAgreementMember2022-07-140001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-03-3100016715022021-09-3000016715022020-12-310001671502qnrx:SkinvisiblelicenseagreementMember2019-10-172019-10-170001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-07-012022-09-300001671502qnrx:OutstandingWarrantsMember2022-07-012022-09-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-01-012022-09-300001671502qnrx:OutstandingWarrantsMember2022-01-012022-09-300001671502us-gaap:WarrantMemberdei:AdrMember2021-07-012021-09-300001671502us-gaap:WarrantMember2021-07-012021-09-300001671502us-gaap:WarrantMemberdei:AdrMember2021-01-012021-09-300001671502us-gaap:WarrantMember2021-01-012021-09-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016715022022-01-012022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000016715022022-04-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-12-310001671502qnrx:AxellaResearchLlcMemberqnrx:ConsultingAgreementMember2021-12-3100016715022022-08-092022-08-0900016715022022-08-102022-08-100001671502qnrx:BridgeNotesMemberus-gaap:PrivatePlacementMember2021-10-282021-10-280001671502qnrx:BridgeNotesMember2021-10-282021-10-280001671502us-gaap:CommonStockMember2022-07-012022-09-300001671502dei:AdrMember2022-07-012022-09-300001671502us-gaap:CommonStockMember2022-04-012022-06-300001671502dei:AdrMember2022-04-012022-06-300001671502us-gaap:CommonStockMember2022-01-012022-03-310001671502dei:AdrMember2022-01-012022-03-3100016715022022-08-012022-08-010001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2018-03-242018-03-240001671502us-gaap:PrivatePlacementMember2021-10-282021-10-280001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-09-300001671502srt:MinimumMember2022-08-010001671502srt:MaximumMember2022-08-010001671502dei:AdrMember2022-08-0100016715022021-12-012021-12-3100016715022021-11-012021-11-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-122022-04-120001671502qnrx:AxellaResearchLlcMemberqnrx:ConsultingAgreementMember2018-07-012018-07-310001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-092022-08-0900016715022021-10-282021-10-280001671502qnrx:OfficersAndFoundersMember2021-10-282021-10-280001671502dei:AdrMember2022-08-100001671502dei:AdrMember2022-06-100001671502qnrx:SeriesBWarrantsAmericanDepositarySharesSeriesCWarrantsExercisedInFullMember2022-03-132022-03-130001671502qnrx:SeriesaWarrantsAmericanDepositarySharesSeriesCWarrantsExercisedInFullMember2022-03-132022-03-1300016715022021-07-012021-09-300001671502qnrx:Notes2020WarrantsMember2022-01-012022-09-300001671502qnrx:BridgeFinancingWarrantsMember2021-01-012021-12-3100016715022022-07-012022-09-300001671502qnrx:BridgeNotesThirdPurchaseMay2021Member2021-03-240001671502qnrx:BridgeNotesSecondPurchaseApril2021Member2021-03-240001671502qnrx:BridgeNotesMember2021-03-240001671502qnrx:BridgeNotesFirstClosingMarch252021Member2021-03-240001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2018-07-012018-07-310001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-09-300001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-05-310001671502qnrx:NethertonSyndromeMemberqnrx:ConsultingAgreementMember2021-11-300001671502qnrx:PolytherapeuticsMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-02-2800016715022021-01-012021-09-300001671502qnrx:BridgeWarrantsCommonStockMember2022-09-300001671502qnrx:SkinvisiblelicenseagreementMember2020-06-300001671502qnrx:SkinvisiblelicenseagreementMember2019-12-310001671502qnrx:AmendmentNumberThreeMemberqnrx:SkinvisiblelicenseagreementMember2021-01-270001671502qnrx:SkinvisiblelicenseagreementMember2021-01-270001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2020-11-012020-11-300001671502us-gaap:RetainedEarningsMember2022-07-012022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2018-03-240001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2022-01-012022-09-300001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2021-01-012021-12-3100016715022022-09-3000016715022021-12-31iso4217:USDxbrli:pureqnrx:itemiso4217:USDxbrli:sharesqnrx:agreementxbrli:sharesqnrx:Yqnrx:Voteqnrx:segment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2022 (No. 2)
Commission File Number 001-37846
QUOIN PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Azrieli Center, Round Tower, 30th Floor
132 Menachem Begin Blvd
Tel Aviv, 6701101
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
Unaudited Interim Financial Statements as of, and for the period ended, September 30, 2022, and Related Management’s Discussion and Analysis of Financial Condition and Results of Operations
On November 10, 2022, Quoin Pharmaceuticals Ltd. (the “Company”) issued unaudited interim financial statements as of, and for the period ended, September 30, 2022, together with the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.
The information in this Form 6-K, including the exhibits hereto, shall be incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos. 333-214817, 333-220015, 333-225003 and 333-232230,), and on Form F-3 (Registration Nos. 333-219614 and 333-229083).
Exhibits
| | |
Exhibit No. | | Exhibit |
99.1 | | Unaudited Interim Financial Statements as of, and for the period ended, September 30, 2022 |
| | |
99.2 | | Management’s Discussion and Analysis of Financial Condition and Results of Operations as of, and for the period ended, September 30, 2022 |
| | |
101 | | Information formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Consolidated Balance Sheets, (ii) Unaudited Consolidated Statements of Operations, (iii) Unaudited Consolidated Statements of Shareholders’ Deficit, (iv) Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
Date: November 10, 2022 | QUOIN PHARMACEUTICALS LTD. |
| | |
| By: | /s/ Gordon Dunn |
| Name: | Gordon Dunn |
| Title: | Chief Financial Officer |
Cellect Biotechnology (NASDAQ:APOP)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Cellect Biotechnology (NASDAQ:APOP)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
Cellect Biotechnology Ltd (나스닥)의 실시간 뉴스: 최근 기사 0
More Quoin Pharmaceuticals, Ltd. News Articles